Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
Robert Nakayama(Keio University), Andrew J. Wagner(Dana-Farber Cancer Institute), Ewa Sicińska(Harvard University), Alex J. Anatone(Dana-Farber Cancer Institute), George D. Demetri(Dana-Farber Cancer Institute), Yi-Xiang Zhang(Harvard University), Jonathan A. Fletcher(Harvard University), Jeffrey T. Czaplinski(Harvard University)
Cited by 75
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996